ORXE Stock UPDATES Ore Pharmaceuticals (ORXE) 0.2500 08/28/2014

New Post Public Reply Private Reply Replies (0) Message Board

Aug 29, 2014 at 12:42 AM

Ore Pharmaceuticals (ORXE) 0.2500 $ORXE

Novavax Announces Management Promotions
Thomson Reuters ONE - Thu Jun 19, 3:26PM CDT
GAITHERSBURG, Md., June 19, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today a number of promotions within its management team.

NYSE Questions Houston American Energy Corp.'s Unusual Market Activity
ACCESSWIRE - Wed Mar 12, 8:25AM CDT
Houston American Energy Corp. (NYSE: HUSA) stock volume soared Mar. 11, with 2,384,313 shares changing hands, nearly five times its three-month average volume of 502,308 shares.

Canfor Corporation and Canfor Pulp Products Inc. Announce Fourth Quarter Results Conference Call
Marketwire - Wed Jan 15, 5:19PM CST
Canfor Corporation (TSX: CFP) and Canfor Pulp Products Inc. (TSX: CFX) will hold a joint conference call on Thursday, February 6, 2014 at 8:00 AM PST to discuss their respective fourth quarter 2013 financial and operating results. To participate in the call, please dial one of the following numbers:

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Functional Dyspepsia
M2 - Mon Sep 02, 9:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lbqxmb/functional_non) has announced the addition of the "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Functional (Non Ulcer) Dyspepsia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Functional (Non Ulcer) Dyspepsia. Functional (Non Ulcer) Dyspepsia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Functional (Non Ulcer) Dyspepsia. - A review of the Functional (Non Ulcer) Dyspepsia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Functional (Non Ulcer) Dyspepsia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Eisai Co., Ltd. - Zeria Pharmaceutical Co Ltd - Ore Pharmaceuticals Inc - AGI Therapeutics plc - Ironwood Pharmaceuticals, Inc. - RaQualia Pharma Inc. For more information visit http://www.researchandmarkets.com/research/lb...tional_non About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Gastric Ulcers - Pipeline Review, H1 2013
M2 - Thu Jul 18, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t63njg/gastric_ulcers) has announced the addition of the "Gastric Ulcers - Pipeline Review, H1 2013" report to their offering. 'Gastric Ulcers - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gastric Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastric Ulcers. Scope - A snapshot of the global therapeutic scenario for Gastric Ulcers. - A review of the Gastric Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gastric Ulcers pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Gastric Ulcers Therapeutics Development - Takeda Pharmaceutical Company Limited - Daewoong Pharmaceutical Co., Ltd. - Eisai Co., Ltd. - Ore Pharmaceuticals Inc - Sihuan Pharmaceutical Holdings Group Ltd. - HeliCure AB Drug Profiles - vonoprazan - DWJ-206 - Helicobacter Pylori Vaccine - ebselen - PMKS-005 - Acid Pump Antagonists - Anaprazole For more information visit http://www.researchandmarkets.com/research/t6...ric_ulcers

Ulcers - Pipeline Review, H1 2013
M2 - Fri Jul 12, 8:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4fgbql/ulcers_pipeline) has announced the addition of the "Ulcers - Pipeline Review, H1 2013" report to their offering. The research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcers. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Scope - A snapshot of the global therapeutic scenario for Ulcers. - A review of the Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-spec

Ore Pharmaceuticals Inc - Product Pipeline Review - 2012
M2 - Mon Feb 18, 4:08AM CST
Summary

Inflammatory Bowel Disease - Pipeline Review, H2 2012 Out Now
M2 - Fri Jan 04, 10:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/pf73r6/inflammatory) has announced the addition of Global Markets Direct's new report "Inflammatory Bowel Disease - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Inflammatory Bowel Disease - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Inflammatory Bowel Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Backdoor Reference Checks: A Hiring Minefield?

What's Really Happening with Job References? Every job seeker has been there, right? You're all set, resume polished to a shine, references lined up like a choir ready to sing your praises, and then bam—you hear that employers are contacting folks you never listed. A new report from Zety highlights this eyebrow-raising trend, and it's got us all questioning the value...

WhiteHorse Set to Redeem Its 2028 Notes Completely

WhiteHorse Finance Divests Its 7.875% Notes Well, WhiteHorse Finance is making some moves, folks. They're planning to redeem their 7.875% notes due in 2028, totaling a cool $34.5 million. This ain't just pocket change, especially with the way markets have been bobbing and weaving lately. The redemption is slated for December 15, 2026, when the notes will get delisted from...

Missoula Inventor Offers Handy Phone Solution on the Move

Adjustable Convenience for the Modern Commuter When you're commuting or just lounging around, less hand strain and more comfort sounds like a no-brainer, right? Well, an inventive soul from Missoula, Montana, just might have cracked this little nut with a gizmo they're calling the COMMUTER PHONE. Imagine never having to juggle your phone during those bumpy moments on the...

Pine AI Unveils AI Studio & Real-World Call Feature

Push Your Expectations: Pine AI Takes the Stage Here's a twist in tech worth a double take. Pine AI is shaking up the AI world with a brash blend of video genius and actual chat capabilities. Somehow, merely weeks after setting the tech scene ablaze with its AI-focused computer, it's already rolling out new applications faster than hotcakes on a skillet. But let’s chew...

CVRx Faces Legal Storm: Investors Grapple with Fallout

CVRx in the Crosshairs: Legal and Operational Woes There's a storm brewing over at CVRx, Inc. (NASDAQ: CVRX), and it's pulling investors down a hell of a financial rabbit hole. You might think you're in the clear with a company like CVRx that boasts approved devices, but think again. Recent revelations have shown that even those with FDA stamps aren't immune to the...

Thanksgiving in Outer Banks: Unique Traditions Await

Thanksgiving Plans Off the Beaten Path Thanksgiving in the Outer Banks isn't just another holiday; it's a whole different ball game. Imagine trading in the usual family couch-potato marathon for a beachside gathering, where the sand replaces the snow, and coastal seafood joins the turkey on your dinner table. If you've been teetering on the edge of making plans, this...

Innovative Rotating Kitchen Organizer Up for Licensing

Dusting Off the Corners: A Fresh Spin on Kitchen Storage Just when you think there's nothing new under the sun when it comes to storing your kitchen gadgets, here comes an invention straight out of Billings, Montana. It's called The Rotating Kitchen Organizer, a nifty contraption that's all set to turn those dead corners into prime real estate. How many times have we...

Custom Upholstered Furniture: Comfort Built to Last

Rethinking Furniture Comfort: Not Just a Luxury Diving into the world of custom upholstered furniture with insights from Randy Marohn is like finding a cheat sheet for comfort. Seriously, it ain't just about plush cushions or slick fabrics—it's a bonafide science. Marohn, from Sans Furniture Inc. in good ol’ Hamburg, NY, unfolds a tale of intentional design and...

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

When to Switch Your LLC to S Corp Status: Tips

Is Your LLC Ready for the S Corp Leap? Thinking about shifting your LLC to S corporation status? You're not alone—many business owners hit this fork in the road as their enterprise starts rolling in more dough. And if you're scratching your head wondering if this switch makes sense for your venture, listen up because timing and context are everything here. When Should...